About ImmunityBio
What ImmunityBio is building
Funding rounds
Total Funding
Last funding round type
Company type
ImmunityBio news and updates
ImmunityBio, Inc. receives financing of $157M in financing
Biotech company ImmunityBio Inc. said it has received $157 million in financing that will provide it with further working capital and support its ongoing business operations.
Dec 12, 2022 | bizjournals.comImmunityBio, Inc. decreases headcount by 38
Patrick Soon-Shiong’s ImmunityBio will lay off 38 employees at the Dunkirk site due to “economic” reasons, according to a WARN notice filed with the state of New York.
Oct 11, 2022 | biospace.comImmunityBio, Inc. invested into assets : Dunkirk site on Jan 1st 22'.
In January, ImmunityBio acquired the Dunkirk site from Athenex, Inc., which was in the process of scaling down operations following failure to win approval of a metastatic breast cancer treatment.
Oct 11, 2022 | biospace.comImmunityBio, Inc. partnered with Athenex, Inc. on Jan 1st 22'.
ImmunityBio, Inc. has signed an agreement with global pharmaceutical company Athenex, Inc. to obtain a leasehold interest in 409,000 square feet of ISO Class 5 pharmaceutical manufacturing space in western New York (the “Dunkirk Facility”), as well as all other related assets.
Jan 23, 2022 | imapac.com